The aim of this study was to evaluate the influence of a degassing step during hot melt extrusion (HME) processing on the physical-mechanical properties of drug-incorporated extrudates. Methods Carbamezapine (CBZ) was selected as a model water insoluble drug and Kollidon ® 17 PF (Polyvinylpyrrolidone) was used as the polymeric carrier. The drug and polymer were blended and subsequently melt extruded using a twin-screw extruder (16 mm Prism EuroLab, ThermoFisher Scientific). The vent port was used for an in-line degassing during the processing. Surface area (Gemini VII, Micromeritics) and true density (AccuPyc II 1340, Micromeritics) of the milled extrudates were measured and porosity was calculated. Differential scanning calorimetry (DSC) was performed to confirm miscibility and morphology of the drug and polymer. Residual moisture was measured by a halogen moisture analyzer balance (MB45 moisture analyzer, Ohaus, USA). In vitro release studies were performed using a USP Type-II dissolution apparatus (Hanson SR8-plus™). Results TGA and DSC data confirmed the thermal stability and amorphous state of all the extrudates. The moisture content of fresh extruded samples was decreased from 6.2% to 0.7% when degassing vent ports were applied. Furthermore, drug content increased after employing the degassing port (from 91.4% to 99.1%). Improved dissolution profiles were observed for extrudates degassed compared to those without degassing. Additionally, optical microscope photographs of fresh extrudates demonstrated improved homogeneity after the degassing process. Finally, melt extrusion degassing positively affected the final products as well as the processing parameters, such as controlling extrusion pressure and torque values.
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Conclusion
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